Dihexa: Research, FDA Status & What We Know

Dihexa—also called PNB-0408—is a synthetic, angiotensin IV–derived research compound. Researchers developed it while looking for molecules that could remain active longer, reach the brain, and support pathways involved in learning, memory, and the formation of connections between neurons.

The early findings were attention-grabbing. Researchers reported increased dendritic-spine and synapse-related measures, improved performance in rodent spatial-learning tasks, and changes in inflammatory and neuronal markers. In plain language, that is where the idea that Dihexa may help the brain “build and strengthen connections” comes from. It is a compelling research direction, especially for scientists studying memory loss and neurodegeneration.

The next challenge is translation. The published findings come from cells and animals, and the record includes important integrity issues: a 2014 mechanism paper was retracted in 2025, while a 2013 characterization paper carries an Expression of Concern. An independent 2021 mouse study nevertheless reported encouraging cognitive, synaptic, and inflammatory signals that support continued investigation.

Dihexa is not hepatocyte growth factor, and it is not a naturally occurring brain protein. It is a small synthetic peptidomimetic derived from an angiotensin IV–related sequence. The early Dihexa work came from a research group at Washington State University and sought to create an analogue that was more metabolically stable and more capable of crossing biological barriers than angiotensin IV itself.

Hepatocyte growth factor, usually shortened to HGF, is a signaling protein with roles in growth, repair, and cell communication. Its receptor is c-Met, also written MET. Researchers proposed that Dihexa could amplify HGF-dependent c-Met signaling and encourage neuronal spine and synapse formation. That is an exciting biological hypothesis. Because the key Dihexa-specific mechanism paper was later retracted, independent laboratories now have an important opportunity to retest and clarify how the compound works.

Identity

Dihexa is a synthetic angiotensin IV–derived peptidomimetic research compound, also known as PNB-0408.

Evidence base

Published work consists of cell and animal studies. FDA reports no identified human exposure data for Dihexa acetate drug products.

Why it is watched

Dihexa remains a closely watched experimental compound because of its potential relevance to memory, neuroplasticity, cognitive aging, and neurodegenerative-disease research.

1. 1

   Building and strengthening connections

   Preclinical work reported increases in dendritic spines and other synapse-related measures in cultured neurons and rodents. These findings helped make Dihexa notable as a possible tool for studying how the brain forms and maintains connections. Independent replication is now needed to define the mechanism and determine whether the signal translates beyond laboratory models.

2. 2

   Memory and learning signals

   In rodent models, researchers reported improvements in spatial-learning and memory tasks, including the Morris water maze. These results are why Dihexa continues to attract interest in cognitive and neurodegenerative-disease research. Human studies would be the essential next step for learning whether the effect is clinically meaningful.

3. 3

   Neuroinflammation and neuronal support

   A 2021 APP/PS1 mouse study reported changes in glial activation, inflammatory cytokines, neuronal markers, and synaptic proteins after Dihexa exposure. Together, those findings suggest several potentially valuable research directions involving inflammation, cell survival, and synaptic function.

4. 4

   Growth-factor and vascular questions

   HGF/c-Met biology intersects with cell growth, tissue repair, and vascular signaling, which helps explain interest in Dihexa’s possible relevance to brain resilience. Claims that it corrects a vascular cause of Alzheimer’s remain untested, but the broader relationship between vascular health, neuronal function, and cognitive aging is a meaningful area for further research.

• Preclinical · formal Expression of Concern

  2013 rat and cell study

  The paper reported that metabolically stabilized angiotensin IV analogues, including Dihexa, improved performance in scopolamine-impaired and aged rat models and increased synapse-related measures. It is the source for many claims that Dihexa is orally active and brain penetrant. PubMed links the paper to a 2021 Expression of Concern, making independent confirmation of these intriguing findings particularly important.

• Evidence history · retracted in 2025

  2014 HGF/c-Met mechanism paper

  This study reported that Dihexa bound HGF, affected c-Met signaling, promoted hippocampal spine and synapse formation, and produced HGF/c-Met-dependent cognitive effects in rodents. The journal retracted the paper in April 2025. Its role today is historical: it explains the proposed mechanism that made Dihexa so interesting and identifies a high-value question for independent laboratories to revisit.

• Evidence history · retracted in 2025

  2012 HGF/Met analogue-development paper

  An earlier paper supporting development of angiotensin IV analogues as HGF/Met modifiers was also retracted in April 2025. That history is important when interpreting the mechanism and highlights the need for a fresh, independent research program.

• Preclinical · APP/PS1 mouse model

  2021 independent Alzheimer’s-model mouse study

  Researchers reported changes in spatial-learning performance, neuronal and synaptic markers, glial activation, inflammatory cytokines, and PI3K/AKT signaling in APP/PS1 mice. The study offers a separate preclinical signal, but it does not establish human efficacy, safety, pharmacokinetics, dosing, or disease modification.

People often encounter Dihexa while looking for better memory, sharper focus, mental energy, healthy cognitive aging, or hope around neurodegenerative disease. Those goals are deeply relatable. They also make it important to understand what may be contributing to a cognitive change, since sleep, mood, medications, metabolic health, hearing, cardiovascular risk, nutrition, and neurologic conditions can all matter.

1. 1

   Describe the change

   Note what changed, when it began, whether it is worsening, and whether daily function, safety, language, movement, or behavior is affected.

2. 2

   Check the evidence level

   Separate human clinical outcomes from cell experiments, animal behavior, mechanistic hypotheses, testimonials, and influencer language.

3. 3

   Use qualified care

   New, progressive, or concerning cognitive symptoms should be discussed with a licensed clinician who can assess causes and evidence-based options.

Influencer videos often describe Dihexa as “the Limitless peptide,” “the ultimate cognitive enhancer,” a way to “build new neural pathways,” or something that could “turn back the brain’s clock.” The language is aspirational, but it connects to real scientific themes—synaptic plasticity, memory, inflammation, and cognitive aging—that researchers have explored in preclinical models.

“Helps your brain build and strengthen connections.”

Preclinical studies reported synapse-related changes, making neuronal connectivity one of Dihexa’s most interesting research themes. Independent confirmation and human research are still needed.

“Could treat Alzheimer’s, Parkinson’s, or dementia.”

Dihexa has been studied in neurodegenerative-disease models, which helps explain the interest. It is not yet an established or FDA-approved treatment for these conditions.

“Turns back the brain’s clock.”

This phrase expresses the hope of supporting cognitive resilience with age. Human studies would need to define whether Dihexa affects any meaningful measure of cognitive aging.